Last reviewed · How we verify
Venous thromboembolic disease
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Venous thromboembolic disease patent landscape — cliff calendar, originator estates, attackable patents
- Venous thromboembolic disease treatment landscape brief
- Venous thromboembolic disease treatment updates RSS
Frequently asked questions about Venous thromboembolic disease
What drugs treat Venous thromboembolic disease?
Tracked treatments include Xarelto.
What is the treatment for Venous thromboembolic disease?
Standard treatment for Venous thromboembolic disease includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Venous thromboembolic disease patent cliff · Venous thromboembolic disease CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing